Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients

Not Applicable

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: Metformin; Drug: Pioglitazone

• Registration Number: NCT01593371
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin), are two major groups of hypoglycemic medications that while function via different pathways, are both effective in short- and long-term glycemic control . These medications diminish or at least delay long term micro- and macrovascular complications associated with prolonged insulin resistance although at different rates. The mechanisms by which this aim is achieved, nevertheless, remains largely unclear. With adipokines playing a key role in development of both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these substances by direct and indirect routes.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-07
• Primary Completion: 2011-10
• Study Completion: 2012-01
• Status Verified: 2012-05
• Study First Submitted: 2012-05-05
• Study First Submitted QC: 2012-05-07
• Study First Posted: 2012-05-08
• Last Update Submitted: 2012-05-08
• Last Update Posted: 2012-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

• Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria (2011) for diagnosis of diabetes

Exclusion Criteria

• previous intake of oral hypoglycemic agents for treatment of diabetes or other hyperglycemia associated conditions
• intake of glucocorticoids in the past one year
• major illnesses of heart, lung, kidney, and liver.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Metformin	Metformin	patients receiving fixed dose metformin 1000 mg daily
Pioglitazone	Pioglitazone	patients receiving fixed dose pioglitazone 30 mg daily

Primary Outcome Measures

Name	Time	Method
Serum concentrations of omentin	12 weeks	Serum concentrations of adipose tissue derived cytokine omentin
Serum concentrations of leptin	12 weeks	Serum concentrations of adipose tissue derived cytokine leptin

Trial Locations

Locations (1)

Tehran University of Medical Sciences; 🇮🇷 Tehran, Iran, Islamic Republic of